117TH CONGRESS 1ST SESSION

H. R. 5224

To amend the Public Health Service Act to authorize grants to eligible entities to develop strategic response plans with respect to the opioid crisis, and to require health care practitioners prescribing an opioid for certain patients to also prescribe an opioid overdose reversal drug, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

SEPTEMBER 10, 2021

Mr. HILL (for himself and Mrs. DINGELL) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the Public Health Service Act to authorize grants to eligible entities to develop strategic response plans with respect to the opioid crisis, and to require health care practitioners prescribing an opioid for certain patients to also prescribe an opioid overdose reversal drug, and for other purposes.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,
- 3 SECTION 1. SHORT TITLE.
- 4 This Act may be cited as the "Preventing Overdoses
- 5 and Saving Lives Act of 2021".

| 1 | SEC. 2. STATE DEMONSTRATION GRANTS FOR COM- |
|----|--|
| 2 | PREHENSIVE OPIOID ABUSE DATA. |
| 3 | Title III of the Public Health Service Act (42 U.S.C. |
| 4 | 241 et seq.) is amended by inserting after section 317U |
| 5 | of such Act (42 U.S.C. 247b–23) the following: |
| 6 | "SEC. 317V. STATE DEMONSTRATION GRANTS FOR COM- |
| 7 | PREHENSIVE OPIOID ABUSE DATA. |
| 8 | "(a) In General.—The Secretary, in conjunction |
| 9 | with the Director of the Centers for Disease Control and |
| 10 | Prevention, may award grants to eligible entities— |
| 11 | "(1) to conduct research and develop a strategic |
| 12 | response plan with respect to the opioid crisis; and |
| 13 | "(2) to establish and implement a co-pre- |
| 14 | scribing program. |
| 15 | "(b) Amount of Grants.— |
| 16 | "(1) IN GENERAL.—The Secretary shall deter- |
| 17 | mine the amount of each grant awarded under this |
| 18 | section on an annual basis. In allocating such |
| 19 | amounts across grantees for a fiscal year, the Sec- |
| 20 | retary shall award— |
| 21 | "(A) a minimum amount to each grantee |
| 22 | in accordance with paragraph (2); and |
| 23 | "(B) an additional amount to each grantee |
| 24 | in accordance with paragraph (3). |
| 25 | "(2) MINIMUM AMOUNT.—The Secretary |
| 26 | shall— |

| 1 | "(A) determine the basis for determining |
|----|---|
| 2 | the minimum amount of a grant under para- |
| 3 | graph $(1)(A)$; and |
| 4 | "(B) apply such basis consistently across |
| 5 | all grantees under this section. |
| 6 | "(3) Additional amount.—In allocating addi- |
| 7 | tional amounts across all grantees under this section |
| 8 | for a fiscal year, the Secretary shall give priority in |
| 9 | setting such amounts to grantees with the highest |
| 10 | opioid dispensing rates as determined by the Centers |
| 11 | for Disease Control and Prevention. |
| 12 | "(c) Priority in Selection.—In selecting grantees |
| 13 | under this section, the Secretary shall give priority to eligi- |
| 14 | ble entities with the highest opioid dispensing rates as de- |
| 15 | termined by the Centers for Disease Control and Preven- |
| 16 | tion. |
| 17 | "(d) Allocation of Funds by a Grantee.—A |
| 18 | grantee under this section shall allocate the funds received |
| 19 | through the grant as follows: |
| 20 | "(1) Not more than 80 percent of the funds re- |
| 21 | ceived through the grant shall be used to conduct re- |
| 22 | search and develop a strategic plan in accordance |
| 23 | with subsection (e). |

| 1 | "(2) At least 20 percent of the grant shall be |
|----|---|
| 2 | used by the grantee to administer a co-prescribing |
| 3 | program in accordance with subsection (f). |
| 4 | "(e) Research; Strategic Plan.— |
| 5 | "(1) In general.—Subject to subsection (d), a |
| 6 | grantee under this section shall use the grant |
| 7 | funds— |
| 8 | "(A) to conduct research on the impacts of |
| 9 | the opioid crisis within the jurisdiction of the |
| 10 | grantee; and |
| 11 | "(B) to develop a strategic plan to respond |
| 12 | to the opioid crisis within such jurisdiction. |
| 13 | "(2) Strategic plan contents.—A strategic |
| 14 | plan required by paragraph (1)(B) shall include |
| 15 | plans for— |
| 16 | "(A) increasing public awareness about the |
| 17 | opioid crisis within the jurisdiction of the grant- |
| 18 | ee; |
| 19 | "(B) full-spectrum prevention within such |
| 20 | jurisdiction; |
| 21 | "(C) intervention within such jurisdiction; |
| 22 | "(D) treatment and recovery within such |
| 23 | jurisdiction; and |
| 24 | "(E) coordinating with law enforcement |
| 25 | within such jurisdiction. |

| 1 | "(f) Co-Prescribing Program.— |
|----|--|
| 2 | "(1) In general.—Subject to subsection (d), a |
| 3 | grantee under this section shall use funds received |
| 4 | through the grant to carry out a co-prescribing pro- |
| 5 | gram under which the grantee requires— |
| 6 | "(A) health care practitioners in the juris- |
| 7 | diction of the grantee who prescribe an opioid |
| 8 | for any patient to also prescribe an opioid over- |
| 9 | dose reversal drug for such patient if— |
| 10 | "(i) the opioid dosage prescribed is |
| 11 | equal to or in excess of 50 morphine milli- |
| 12 | gram equivalents per day; |
| 13 | "(ii) the practitioner prescribes a |
| 14 | benzodiazepine for the patient or knows or |
| 15 | reasonably should know a benzodiazepine |
| 16 | has been prescribed for the patient in the |
| 17 | past; |
| 18 | "(iii) the practitioner prescribes medi- |
| 19 | cation-assisted treatment for the patient or |
| 20 | knows or reasonably should know medica- |
| 21 | tion assisted treatment has been prescribed |
| 22 | for the patient in the past; or |
| 23 | "(iv) the practitioner knows or rea- |
| 24 | sonably should know the patient has a his- |
| 25 | tory of substance use disorder; |

- 1 "(B) such health care practitioners to com-2 plete continuing education on opioid pre-3 scribing; and
- "(C) coroners in the jurisdiction of the grantee to complete continuing education on recognizing fatalities attributable to an opioid overdose.
- "(2) WAIVER.—If the laws, regulations, or orders of an applicant for a grant under this section conflict in any respect with the requirements of subparagraph (A), (B), or (C) of paragraph (1), the Secretary shall waive such requirements to the extent necessary to allow the grantee to carry out a coprescribing program under this section.
- "(g) SUPPLEMENT, NOT SUPPLANT.—Grant funds under this section shall be used to supplement, not suplant, funding from other sources for the activities funded through the grant.
- "(h) APPLICATION.—To seek a grant under this sec-20 tion, an eligible entity shall submit an application at such 21 time, in such manner, and containing such information 22 and assurances as the Secretary may require.
- "(i) Reporting.—Not later than the end of each of 24 fiscal years 2024 and 2026, a grantee under this section 25 shall submit to the Secretary, the Director of the Centers

for Disease Control and Prevention, and the appropriate 2 congressional committees, and make publicly available, a 3 report on the activities funded through the grant for each 4 fiscal year covered by the report, including— "(1) the allocation of funds for activities under 5 6 subsection (e) versus activities under subsection (f); "(2) a description of the research conducted by 7 8 the grantee under subsection (e)(1)(A), including the 9 results of such research; "(3) an up-to-date version of the strategic plan 10 11 developed under subsection (e)(1)(B); and "(4) a description of the co-prescribing program 12 13 under subsection (f), including an analysis of the ef-14 fectiveness of the program. "(j) Definitions.—In this section: 15 "(1) Appropriate congressional commit-16 17 TEES.—The term 'appropriate congressional com-18 mittees' means the Committee on Energy and Com-19 merce of the House of Representatives and the Com-20 mittee on Housing, Education, Labor, and Pensions 21 of the Senate. 22 "(2) ELIGIBLE ENTITY.—The term 'eligible en-23 tity' means any State, any Indian Tribe, the District

of Columbia, or any territory of the United States.

24

| 1 | "(3) Indian Tribe.—The term 'Indian Tribe' |
|----|---|
| 2 | has the meaning given to such term in section 4 of |
| 3 | the Indian Self-Determination and Education Assist- |
| 4 | ance Act. |
| 5 | "(4) Opioid overdose reversal drug.—The |
| 6 | term 'opioid overdose reversal drug' means— |
| 7 | "(A) naloxone; or |
| 8 | "(B) any other emergency opioid antago- |
| 9 | nist approved by the Food and Drug Adminis- |
| 10 | tration to treat an opioid overdose. |
| 11 | "(k) Authorization of Appropriations.—To |
| 12 | carry out this section, there are authorized to be appro- |
| 13 | priated such sums as may be necessary for each of fiscal |
| 14 | vears 2022 through 2026 " |